Department of Radiotherapy, The Affiliated Hospital of Inner Mongolia Medical University, No. 1 Tongdao North Street, Hohhot, 010050, China.
World J Surg Oncol. 2023 Oct 26;21(1):339. doi: 10.1186/s12957-023-03209-0.
To determine the efficacy of adjuvant radiotherapy for stage II-III biliary tract carcinoma.
We retrospectively analyzed the data of 37 patients who underwent radical resection of biliary tract carcinomas at the Affiliated Hospital of Inner Mongolia Medical University between 2016 and 2020. We analyzed survival differences between patients who did (n = 17) and did not (n = 20) receive postoperative adjuvant radiotherapy by using Kaplan-Meier analysis. The log-rank test and Cox univariate analysis were used. The Cox proportional risk regression model was used for the multifactorial analysis of factors influencing prognosis.
The median survival time (28.9 vs. 14.5 months) and the 1-year (82.40% vs. 55.0%) and 2-year survival rates (58.8% vs. 25.0%) were significantly higher among patients who received adjuvant radiotherapy than among those who did not (χ = 6.381, p = 0.012). Multifactorial analysis showed that pathological tumor type (p = 0.004), disease stage (p = 0.021), and adjuvant radiotherapy (p = 0.001) were independent prognostic factors in biliary tract carcinoma. Subgroup analyses showed that compared to no radiotherapy, adjuvant radiotherapy significantly improved median survival time in patients with stage III disease (21.6 vs. 12.7 months; p = 0.017), positive margins (28.9 vs. 10.5 months; p = 0.012), and T3 or T4 tumors (26.8 vs. 16.8 months; p = 0.037).
Adjuvant radiotherapy significantly improved the survival of patients with biliary tract carcinoma, and is recommended especially for patients with stage III disease, positive surgical margins, or ≥ T3.
为了确定辅助放疗对 II-IIIb 期胆道癌的疗效。
我们回顾性分析了 2016 年至 2020 年间在内蒙古医科大学附属医院接受根治性胆道癌切除术的 37 例患者的数据。我们通过 Kaplan-Meier 分析比较了接受（n=17）和未接受（n=20）术后辅助放疗的患者之间的生存差异。对数秩检验和 Cox 单因素分析用于生存分析。Cox 比例风险回归模型用于影响预后的多因素分析。
接受辅助放疗的患者中位生存时间（28.9 个月比 14.5 个月）、1 年（82.40%比 55.0%）和 2 年生存率（58.8%比 25.0%）均显著高于未接受放疗的患者（χ²=6.381，p=0.012）。多因素分析显示，病理肿瘤类型（p=0.004）、疾病分期（p=0.021）和辅助放疗（p=0.001）是胆道癌的独立预后因素。亚组分析显示，与未放疗相比，辅助放疗显著提高了 III 期疾病（21.6 个月比 12.7 个月；p=0.017）、阳性切缘（28.9 个月比 10.5 个月；p=0.012）和 T3 或 T4 肿瘤（26.8 个月比 16.8 个月；p=0.037）患者的中位生存时间。
辅助放疗显著提高了胆道癌患者的生存率，尤其推荐用于 III 期疾病、阳性手术切缘或≥T3 的患者。
